Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kooth plc (KOO.L)
London, BJ, GB
Kooth plc, together with its subsidiaries, provides digital mental health services to children, young people, and adults in the United Kingdom. It operates online platforms that offers various therapeutic support and interventions, including anonymous and personalised mental health support; and a community with a library of peer and professional created content, as well as provides online counselling, coaching, and support services under the Kooth, Qwell, and Soluna names. The company was founded in 2001 and is headquartered in London, the United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.59% | -1.15% | +33.46% | +42.92% | +40.00% | +49.13% | -2.00% | -30.57% | -52.75% | -28.54% | -28.54% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%-5.2% Q4'25: +43.9% (vs Q4'23)
-
EPS growth Medical - Care Facilities: +19.2%-67.8% Q4'25: +920.4% (vs Q4'23)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+7.3% Q4'25: +32.0% (vs Q4'23)
-
EBIT margin Medical - Care Facilities: +11.3%+6.4% Q4'25: +16.3% (vs Q4'23)
-
ROIC Medical - Care Facilities: +6.8%+24.2% ★ Q4'25: +128.9% (vs Q4'23)
-
Share dilution Medical - Care Facilities: +0.0%-1.1% ★ Q4'25: +3.5% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×0.00× ★ Q4'25: 0.00× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 3 EPS Ana. |
Dec 2027 4 Rev. Ana. 3 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
13.01M
est: 12.75M (+2.1%)
|
16.68M
est: 16.51M (+1.1%)
|
20.12M
est: 19.97M (+0.8%)
|
33.34M
est: 54.17M (-38.5%)
|
66.74M
est: 65.52M (+1.9%)
|
63.29M
est: 63.30M (0.0%)
|
63.13M
63.00M – 63.30M
-0.3% YoY
|
61.75M
59.41M – 66.01M
-2.2% YoY
|
67.50M
66.16M – 69.89M
+9.3% YoY
|
| EBITDA |
-133.0K
est: 1.07M (-112.5%)
|
1.65M
est: 1.38M (+19.7%)
|
1.32M
est: 1.67M (-20.6%)
|
1.51M
est: 6.39M (-76.3%)
|
14.53M
est: 7.72M (+88.2%)
|
10.23M
est: 7.46M (+37.0%)
|
7.44M
7.43M – 7.46M
-0.3% YoY
|
7.28M
7.00M – 7.78M
-2.2% YoY
|
7.96M
7.80M – 8.24M
+9.3% YoY
|
| EBIT |
-1.63M
est: -370.0K (-340.8%)
|
-733.0K
est: -479.0K (-53.0%)
|
-912.0K
est: -579.4K (-57.4%)
|
-2.26M
est: 475.9K (-575.3%)
|
9.16M
est: 575.5K (+1,490.9%)
|
4.03M
est: 556.1K (+624.6%)
|
554.5K
553.4K – 556.0K
-0.3% YoY
|
542.4K
521.9K – 579.9K
-2.2% YoY
|
593.0K
581.2K – 614.0K
+9.3% YoY
|
| Net Income |
-1.48M
est: -1.80M (+17.8%)
|
-310.0K
est: -982.7K (+68.5%)
|
-716.0K
est: -648.5K (-10.4%)
|
-169.0K
est: 4.56M (-103.7%)
|
8.03M
est: 5.73M (+40.3%)
|
2.61M
est: 3.16M (-17.6%)
|
3.16M
2.73M – 3.59M
0.0% YoY
|
4.23M
3.62M – 4.83M
+33.6% YoY
|
4.60M
4.43M – 4.76M
+8.8% YoY
|
| SGA |
2.41M
est: 6.87M (-65.0%)
|
9.93M
est: 8.90M (+11.7%)
|
12.53M
est: 10.76M (+16.4%)
|
24.34M
est: 33.36M (-27.0%)
|
37.46M
est: 40.35M (-7.2%)
|
36.06M
est: 38.99M (-7.5%)
|
38.88M
38.80M – 38.98M
-0.3% YoY
|
38.03M
36.59M – 40.65M
-2.2% YoY
|
41.57M
40.75M – 43.05M
+9.3% YoY
|
| EPS |
-0.04
est: -0.05 (+3.0%)
|
-0.01
est: -0.03 (+62.7%)
|
-0.02
est: -0.02 (-31.5%)
|
0.00
est: 0.12 (-104.2%)
|
0.22
est: 0.15 (+49.6%)
|
0.07
est: 0.08 (-11.9%)
|
0.09
0.07 – 0.09
+7.3% YoY
|
0.11
0.09 – 0.13
+26.6% YoY
|
0.12
0.11 – 0.12
+6.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-15 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-14 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-13 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-05 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-01 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kate Newhouse | Chief Executive Officer & Executive Director | 767.0K | female |
| Sanjay Jawa | Chief Financial Officer & Executive Director | 669.0K | male |
| Kurt Seefeld | Chief Product & Technology Officer | — | — |
| Lynne Green | Chief Clinical Officer | — | — |
| Patrick Johnston | Chief Operating Officer | — | — |
| Richard Macmillan | Head of Legal and Risk | — | male |
| Bo Peng | Head of Data Science | — | female |
| Siobhan Halford | Director of People | — | — |
| Katherine Beihl | Chief Marketing Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KOO.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
